The Big Question: A Synergistic Partnership So, now we have our two players
For instance, it is an inhibitor of c-Jun N-terminal kinase (JNK) whose activation leads to c-Jun phosphorylation 25
Our study implicates that targeting the estrogen-dependent system x c , specifically SLC7A11 and SLC3A2, with IKE through induction of ferroptosis in ER+ breast cancer cells, should offer a new therapeutic option for patients with ER+ breast cancer, particularly those with endocrine resistance
These include subcutaneous immunotherapy (SCIT) and sublingual immunotherapies (SLIT) [122]
tenella soluble protein extracts exhibited potent immunostimulatory effects, antitumor effects, and the ability to induce IL-12, leading to increased mice survival, reduced tumor size, and high cure rates
Drayton, R